Stock Events

Stock Events

Algernon Pharmaceuticals 

$0.3
12
+$0.01+3.96% Monday 13:30

Statistics

Day High
0.3
Day Low
0.3
52W High
0.37
52W Low
0.02
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

24JulExpected
Q2 2024
Q4 2024
Q1 2025
Q2 2025
Q4 2025
Next
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-382,644.02Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AGNPF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap27.62B
Biogen focuses on neurology, a field relevant to Algernon Pharmaceuticals' interest in neurological diseases, making them direct competitors in research and development of treatments.
Lilly(Eli) &
LLY
Mkt Cap862.01B
Eli Lilly and Company has a strong portfolio in neuroscience and psychiatric medications, areas that Algernon Pharmaceuticals is also exploring, positioning them as competitors.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has a broad range of pharmaceutical products, including treatments for conditions that Algernon Pharmaceuticals is targeting, making them competitors in multiple therapeutic areas.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. competes in the development of drugs for diseases that Algernon Pharmaceuticals is also interested in, such as neurological and respiratory diseases.
Novartis
NVS
Mkt Cap279.67B
Novartis AG has a diversified portfolio, including treatments for neurological conditions, directly competing with Algernon Pharmaceuticals' research interests.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences, Inc. is involved in the development of treatments for viral infections, an area that Algernon Pharmaceuticals has shown interest in, making them competitors.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie Inc. works on neuroscience among other areas, directly competing with Algernon Pharmaceuticals in the development of treatments for neurological conditions.
AMGEN
AMGN
Mkt Cap178B
Amgen Inc. has a focus on innovative therapeutics, including areas that overlap with Algernon Pharmaceuticals' interests, positioning them as competitors.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.7B
Teva Pharmaceutical Industries Limited operates in generic and specialty medicines, including areas of interest to Algernon Pharmaceuticals, making them indirect competitors.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in various therapeutic areas, including those targeted by Algernon Pharmaceuticals, making them a broad competitor.

About

Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non–alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, pancreatic and small cell lung cancer, and acute lung injury in Canada, Australia, and New Zealand. The company's pipeline includes Ifenprodil, which completed Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in preclinical stage for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which has completed preclinical stage for the treatment of strokes. The company was formerly known as “Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Show more...
CEO
Mr. Christopher J. Moreau
Employees
5
Country
United States

Listings

CN
CA
GREY.CN
MU
DE
AGW0.MU
STU
DE
AGW0.STU
OTC Link
US
AGNPD

0 Comments

Share your thoughts

FAQ

What is Algernon Pharmaceuticals stock price today?▼
The current price of AGNPF is $0.3 USD — it has increased by +3.96% in the past 24 hours. Watch Algernon Pharmaceuticals stock price performance more closely on the chart.
What is Algernon Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Algernon Pharmaceuticals stocks are traded under the ticker AGNPF.
Is Algernon Pharmaceuticals stock price growing?▼
AGNPF stock has risen by +10.7% compared to the previous week, the month change is a -21.32% fall, over the last year Algernon Pharmaceuticals has showed a -54.66% decrease.
When is the next Algernon Pharmaceuticals earnings date?▼
Algernon Pharmaceuticals is going to release the next earnings report on July 24, 2026.
What is Algernon Pharmaceuticals revenue for the last year?▼
Algernon Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Algernon Pharmaceuticals net income for the last year?▼
AGNPF net income for the last year is -382,644.02 USD.
How many employees does Algernon Pharmaceuticals have?▼
As of May 06, 2026, the company has 5 employees.
In which sector is Algernon Pharmaceuticals located?▼
Algernon Pharmaceuticals operates in the Health & Wellness sector.
When did Algernon Pharmaceuticals complete a stock split?▼
The last stock split for Algernon Pharmaceuticals was on April 21, 2026 with a ratio of 1:10.
Where is Algernon Pharmaceuticals headquartered?▼
Algernon Pharmaceuticals is headquartered in Vancouver, United States.